BioCentury
ARTICLE | Financial News

Dynavax spikes on Heplisav-B FDA panel vote

July 31, 2017 8:58 PM UTC

Dynavax Technologies Corp. (NASDAQ:DVAX) jumped $6.60 (71%) to $15.85 on Monday after FDA's Vaccines and Related Biological Products Advisory Committee voted Friday that available safety data support the use of the company's HBV vaccine Heplisav-B in adults (see BioCentury Extra, July 28)...

BCIQ Company Profiles

Dynavax Technologies Corp.